SCHEMBL564833

SCHEMBL564833

CC(C)(Cc1ccc(F)cc1Cl)NC=O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.40
PGR P06401 2/20 0.40
NR3C2 P08235 2/20 0.40
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
P2RX7 Q99572 10/20 0.37
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564307 0.84 RIPK1 (0.40) ALDH1A1SMN1; SMN2POLB
SCHEMBL565200 0.83 P2RX7 (0.34) NR3C1NR3C2ALDH1A1P2RX7
SCHEMBL9767974 0.80 NR3C1 (0.42) NR3C1PGRNR3C2ALDH1A1SMN1; SMN2
SCHEMBL2600032 0.77 NR3C1 (0.42) NR3C1PGRNR3C2ALDH1A1SMN1; SMN2
SCHEMBL8824455 0.74 KDM4E (0.42) ALDH1A1LMNAL3MBTL1CYP2C19
SCHEMBL564445 0.74 NR3C1 (0.46) NR3C1PGRNR3C2ALDH1A1SMN1; SMN2
SCHEMBL564609 0.74 NPC1 (0.43) NR3C1PGRNR3C2ALDH1A1SMN1; SMN2
SCHEMBL1720925 0.74 POLQ (0.45) ALDH1A1SMN1; SMN2HTTP2RX7NPC1
SCHEMBL25039130 0.72 P2RX7 (0.40) NR3C1PGRNR3C2ALDH1A1SMN1; SMN2
SCHEMBL17574522 0.72 P2RX7 (0.45) ALDH1A1SMN1; SMN2LMNAHTTP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562603-B3 NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES BOEHRINGER INGELHEIM PHARMA (DE) 2014-01-08 EP disclosed
EP-1765355-B1 BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES BOEHRINGER INGELHEIM INT (DE) 2013-03-06 EP disclosed
US-20120035169-A1 AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-09 US disclosed
US-8044046-B2 Medicaments for the treatment of chronic obstructive pulmonary disease BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) 2011-10-25 US disclosed
CN-101817800-A Novel medicaments for the treatment of chronic obstructive pulmonary diseases BOEHRINGER INGELHEIM PHARMA 2010-09-01 CN disclosed
US-7786111-B2 Medicaments for the treatment of chronic obstructive pulmonary disease BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-08-31 US disclosed
CN-101735166-A Novel medicaments for the treatment of chronic obstructive pulmonary diseases BOEHRINGER INGELHEIM PHARMA 2010-06-16 CN disclosed
US-7727984-B2 R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino ]-ethyl}-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof; betamimetics; for administration once a day for treating COPD BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2010-06-01 US disclosed
US-20090181961-A1 NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-16 US disclosed
EP-1562603-B1 NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES BOEHRINGER INGELHEIM PHARMA (DE) 2009-05-06 EP disclosed
US-20070155741-A1 Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-07-05 US disclosed
CN-1946406-A Benzoxazines for treating respiratory diseases BOEHRINGER INGELHEIM INT (DE) 2007-04-11 CN disclosed
US-7056916-B2 Medicaments for the treatment of chronic obstructive pulmonary disease BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-06-06 US disclosed
US-20060106213-A1 New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-05-18 US disclosed
CN-1713914-A Novel drug for treating chronic obstructive pulmonary disease BOEHRINGER INGELHEIM PHARMA (DE) 2005-12-28 CN disclosed
US-20050272726-A1 Novel medicaments for the treatment of respiratory diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-08 US disclosed
US-20050256115-A1 Aerosol formulation for the inhalation of beta-agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-17 US disclosed
US-20050239778-A1 Novel medicament combinations for the treatment of respiratory diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2005-10-27 US disclosed
US-20050222144-A1 Medicaments for the treatment of chronic obstructive pulmonary disease BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-10-06 US disclosed
US-20040147513-A1 New medicaments for the treatment of chronic obstructive pulmonary disease BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256115-A1 Aerosol formulation for the inhalation of beta-agonists ADRB1, ADRB2, ADRB3 NR3C1 618/4885PGR 1291/4885NR3C2 471/4885
US-20060106213-A1 New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease SLC26A4, CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 NR3C1 176/4885PGR 2291/4885NR3C2 55/4885
US-20090181961-A1 NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES MRGPRX2, MRGPRX1, CFTR NR3C1 283/4885PGR 2086/4885NR3C2 187/4885
US-20050222144-A1 Medicaments for the treatment of chronic obstructive pulmonary disease H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 NR3C1 90/4885PGR 1459/4885NR3C2 20/4885
US-20050272726-A1 Novel medicaments for the treatment of respiratory diseases MRGPRX2, MRGPRX1, CFTR NR3C1 283/4885PGR 2086/4885NR3C2 187/4885
US-20040147513-A1 New medicaments for the treatment of chronic obstructive pulmonary disease CLIC1, OTC, SLC10A1 NR3C1 115/4885PGR 3418/4885NR3C2 103/4885
US-20050239778-A1 Novel medicament combinations for the treatment of respiratory diseases MRGPRX2, MRGPRX1, MTNR1B NR3C1 101/4885PGR 2259/4885NR3C2 33/4885
US-20120035169-A1 AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS ADRB1, ADRB2, ADRB3 NR3C1 618/4885PGR 1291/4885NR3C2 471/4885
US-20070155741-A1 Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 NR3C1 90/4885PGR 1459/4885NR3C2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.